Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trialsRobert E. Shapiro, Amaal J. Starling, Rashna Khanna et al.|The Journal of Headache and Pain|2019Cited by 88
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controlsEric Pearlman, Gary G. Kay, Darren Wilbraham et al.|Human Psychopharmacology Clinical and Experimental|2020Cited by 63
Clinical safety of the selective PKC-β inhibitor, ruboxistaurinJanet B. McGill, David L. Hyslop, Edward J. Bastyr et al.|Expert Opinion on Drug Safety|2006Cited by 48